Back to top

EU opinion ‘headwind, but not insurmountable’ for Zevra, says H.C. Wainwright

After Zevra Therapeutics (ZVRA) announced that the EMA’s Committee for Medicinal Products for Human Use adopted a negative opinion on the marketing...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Zevra Therapeutics, Inc. (ZVRA)